Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  H. Lundbeck    LUN   DK0010287234

H. LUNDBECK (LUN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
02/19/2018 02/20/2018 02/21/2018 02/22/2018 02/23/2018 Date
320(c) 321.1(c) 326.5(c) 323.1(c) 319.1(c) Last
193 209 309 390 278 753 488 300 382 291 Volume
-1.23% +0.34% +1.68% -1.04% -1.24% Change
More quotes
Financials ( DKK)
Sales 2018 17 769 M
EBIT 2018 5 231 M
Net income 2018 3 543 M
Finance 2018 5 163 M
Yield 2018 3,52%
Sales 2019 17 466 M
EBIT 2019 4 958 M
Net income 2019 3 438 M
Finance 2019 6 546 M
Yield 2019 3,65%
P/E ratio 2018 18,31
P/E ratio 2019 18,78
EV / Sales2018 3,37x
EV / Sales2019 3,35x
Capitalization 64 989 M
More Financials
Company
H. Lundbeck A/S engages in the research, development, and market of pharmaceutical products for the treatment of psychiatric and neurological disorders.It operates through the following geographical segments: Europe, the Unites States of America, and International Markets.Its product portfolio... 
Sector
Pharmaceuticals
Calendar
03/20Shareholder meeting
More about the company
Surperformance© ratings of H. Lundbeck
Trading Rating : Investor Rating :
More Ratings
Latest news on H. LUNDBECK
02/21H LUNDBECK : Lundbeck increases its share capital by 8,668 shares as a result of..
AQ
02/20H LUNDBECK : Lundbeck increases its share capital by 8,668 shares (0.0044 % of o..
AQ
02/15H LUNDBECK : New Neurochemistry Findings Has Been Reported by Investigators at H..
AQ
02/07H LUNDBECK : Annual Report 2017 for H. Lundbeck A/S
AQ
02/07H LUNDBECK : Lundbeck delivers its best financial results following 10% revenue ..
AQ
01/19H LUNDBECK : Patent Issued for 1-piperazine as a Compound with Combined Serotoni..
AQ
01/08H LUNDBECK : Lundbeck enters research partnership on novel treatment of schizoph..
AQ
01/05H LUNDBECK : Lundbeck enters research partnership on novel treatment of schizoph..
PU
01/05LUNDBECK ENTERS RESEARCH PARTNERSHIP : New partnership with Vanderbilt Universit..
AQ
2017H LUNDBECK : Lundbecks Brintellix approved in China
AQ
More news
Sector news : Pharmaceuticals - NEC
01:46pPUMA BIOTECHNOLOGY : EU panel recommends against nod for Puma Biotech's breast c..
RE
12:30pSANOFI : Says U.S. Waiting Period for Bioverativ Has Expired
DJ
11:10aSHIRE : FDA to Conduct Priority Review of Shire Genetic-Disorder Drug
DJ
08:48aNOVARTIS : Greek Parliament Approves Bribery and Price Fix Inquiry on Novartis -..
DJ
02/22NOVARTIS : Greek Parliament Investigates Politicians in Novartis Bribery Probe
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
02/20H. Lundbeck A/S: Lundbeck increases its share capital by 8,668 shares (0.0044.. 
02/14$HLUYY - Jefferies Group Analysts Lower Earnings Estimates for H. Lundbeck A/.. 
02/12Jefferies Group Lowers H. Lundbeck A/S- FY2021 Earnings Estimates to $2.99 EP.. 
02/09Jefferies Group Sets H. Lundbeck A/S- Q1 2018 Earnings Estimates at $0.81 EPS.. 
01/20H. Lundbeck A/S- upgraded by Zacks Investment Research to strong-buy. $58.00 .. 
More tweets
Qtime:22
News from SeekingAlpha
02/09Lundbeck Looks Largely Played Out 
02/07H. Lundbeck A/S ADR 2017 Q4 - Results - Earnings Call Slides 
02/07H. Lundbeck A/S reports Q4 results 
02/02Dr. Reddy's launches generic Xenazine in U.S. 
2017Teva's Restructuring Plan 
Chart H. LUNDBECK
Duration : Period :
H. Lundbeck Technical Analysis Chart | LUN | DK0010287234 | 4-Traders
Technical analysis trends H. LUNDBECK
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 303  DKK
Spread / Average Target -7,1%
EPS Revisions
Managers
NameTitle
Anders Götzsche Executive VP, Chief Executive & Financial Officer
Lars Søren Rasmussen Chairman
Lars Bang Executive VP-Supply Operations & Engineering
Anders Gersel Pedersen Executive Vice President-Research & Development
Jørn Møller Mayntzhusen Director & Senior Manager-Supply Optimization
Sector and Competitors
1st jan.Capitalization (M$)
H. LUNDBECK2.57%10 734
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%224 221
PFIZER-1.27%213 155
ROCHE HOLDING LTD.-9.41%207 327
MERCK AND COMPANY-3.06%148 618